The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.
Researchers from UVA Cancer Center, the University of Virginia School of Medicine, and Inova Peterson Life with Cancer detail the many ways artificial intelligence could help ensure patients receive the support they need.
